Your browser doesn't support javascript.
loading
Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma.
Oliver, Jamie R; Lieberman, Seth M; Tam, Moses M; Liu, Cheng Z; Li, Zujun; Hu, Kenneth S; Morris, Luc G T; Givi, Babak.
Afiliação
  • Oliver JR; New York University School of Medicine, New York, New York.
  • Lieberman SM; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, New York.
  • Tam MM; Department of Radiation Oncology, NYU Langone Health, New York, New York.
  • Liu CZ; Department of Pathology, NYU Langone Health, New York, New York.
  • Li Z; Department of Medical Oncology, NYU Langone Health, New York, New York.
  • Hu KS; Department of Radiation Oncology, NYU Langone Health, New York, New York.
  • Morris LGT; Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Givi B; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, New York.
Cancer ; 126(7): 1413-1423, 2020 04 01.
Article em En | MEDLINE | ID: mdl-31886908
ABSTRACT

BACKGROUND:

To the authors' knowledge, the question of whether human papillomavirus (HPV) infection is associated with outcomes in patients with sinonasal squamous cell carcinoma (SNSCC) is not well studied at this time. In the current study, the authors investigated patterns of HPV testing and its association with survival in patients with SNSCC using the National Cancer Data Base.

METHODS:

The authors selected all SNSCC cases diagnosed between 2010 and 2016. HPV testing practices, clinicodemographic factors, treatments, and survival were analyzed. Multivariable Cox regression and propensity score-matched survival analyses were performed.

RESULTS:

A total of 6458 SNSCC cases were identified. Of these, only 1523 cases (23.6%) were tested for HPV and included in the current study. The median patient age was 64 years and the majority had advanced stage tumors (overall AJCC stage III-IV, 721 patients; 62.1%). HPV-positive SNSCC comprised 31.5% (447 of 1418 cases) of the final study cohort. Among 15 hospitals that routinely tested nonoropharyngeal SCCs for HPV, the percentage of HPV-positive SNSCCs was smaller (24.6%; P = .04). Patients with HPV-positive SNSCC were younger (aged 60 years vs 65 years; P < .001), with tumors that were more likely to be high grade (55.3% vs 41.7%; P < .001), and attributed to the nasal cavity (62.2% vs 44.0%; P < .001). HPV-positive SNSCC was associated with significantly improved overall survival in multivariable regression analysis (hazard ratio, 0.45; 95% CI, 0.28-0.72 [P = .001]) and propensity score-matched (hazard ratio, 0.61; 95% CI, 0.38-0.96 [P = .03]) analyses controlling for clinicodemographic and treatment factors.

CONCLUSIONS:

Currently, only a minority of patients with SNSCC are tested for HPV. However, a sizable percentage of SNSCC cases may be HPV related; furthermore, HPV-positive SNSCC is associated with improved overall survival. Routine HPV testing may be warranted in patients with SNSCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Nasais / Infecções por Papillomavirus / Carcinoma de Células Escamosas de Cabeça e Pescoço Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Nasais / Infecções por Papillomavirus / Carcinoma de Células Escamosas de Cabeça e Pescoço Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article